Why Insulin Costs Still Crush Americans Despite State Price Caps

Insulin costs remain a heavy burden for millions of Americans, despite recent efforts to lower prices. While 23 states have set monthly copay caps between $25 and $100, many still struggle with high expenses. A bipartisan federal bill now aims to expand these protections nationwide. Across the U.S., insulin prices vary sharply. In Mississippi, a toddler's one-month supply of vials and a three-month backup of pens cost his parents $194 last week. His mother, Marlee Brandon, fears these costs will only rise over time.

For adults, the strain is just as real. Breana Glover, a 23-year-old with Type 1 diabetes, pays a $50 copay for just four vials. She is one of roughly 8.1 million Americans who rely on insulin, including over 2 million with Type 1 diabetes. Major manufacturers like Eli Lilly, Sanofi, and Novo Nordisk have begun reducing prices. But state-level caps—ranging from $25 in Colorado and Illinois to $100 in Texas—don't cover everyone. About 57% of Americans with private insurance have self-insured plans, which fall outside state regulations. The proposed INSULIN Act would cap monthly costs at $35 for those with private insurance. It would also launch a pilot program in 10 states to help uninsured Americans access cheaper insulin.

If passed, the INSULIN Act would extend cost protections to millions currently left out of state caps. For now, many still face steep monthly bills, with no guarantee of long-term relief. The bill's success could determine whether more families can afford this life-saving medication.